Targeting hypoxia in cancer therapy
The DOI matches its Crossref record; 190 of the 190 references it cites were found in a registry or an index.
Abstract
Hypoxia is a feature of most tumours, albeit with variable incidence and severity within a given patient population. It is a negative prognostic and predictive factor owing to its multiple contributions to chemoresistance, radioresistance, angiogenesis, vasculogenesis, invasiveness, metastasis, resistance to cell death, altered metabolism and genomic instability. Given its central role in tumour progression and resistance to therapy, tumour hypoxia might well be considered the best validated target that has yet to be exploited in oncology. However, despite an explosion of information on hypoxia, there are still major questions to be addressed if the long-standing goal of exploiting tumour hypoxia is to be realized. Here, we review the two main approaches, namely bioreductive prodrugs and inhibitors of molecular targets upon which hypoxic cell survival depends. We address the particular challenges and opportunities these overlapping strategies present, and discuss the central importance of emerging diagnostic tools for patient stratification in targeting hypoxia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several approaches for targeting hypoxic tumor cells have been proposed including hypoxia-activated prodrugs, gene therapy, recombinant anaerobic bacteria, specific targeting of HIFs, or targeting pathways important in hypoxic cells such as the mTOR and UPR pathways (Melillo, 2007;Wilson & Hay, 2011;Semenza, 2012).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Wilson & Hay, 2011
In the citing paper
“Endothelial cells, fibroblasts, and immune cells are the three main cell types which appear in most cancers and are vital components in enhancing the drug resistance of tumors [103, 114-120].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [120]
In the citing paper
“Endothelial cells, fibroblasts, and immune cells are the three main cell types which appear in most cancers and are vital components in enhancing the drug resistance of tumors [103, 114-120].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [120]
In the citing paper
“Hypoxic environment, on the other hand, is known to reduce cytotoxicity of many anticancer drugs, affect angiogenesis, promote metastasis and alter the metabolic activity of cancer cells [183,197].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [183]
In the citing paper
“In addition to increasing drug resistance, a high SS could influence tumor cells' gene expression, comprise immune cells ability to kill cancerous cells or even turn macrophages to tumorfriendly cells, thereby enhancing the metastatic potential of cancer cells [180-184].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [183]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717 · cited 1×
“The two main oxygen-responsive signalling pathways that mediate adaptation to hypoxia are centred on the HIF family of transcription factor”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“Initially, hypoxia arises because of oxygen diffusion limitations in avascular primary tumours or their metastases, but the tumour microvasculature (induced in part as a response to this hypoxia) is highly abnorma”
BackgroundNetwork medicine: a network-based approach to human disease
Barabási, A.-L., Gulbahce, N., & Loscalzo, J. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2918 · Cited by 5,034
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J. (1996) · Nature · doi:10.1038/379088a0 · Cited by 2,300
DNA repair pathways as targets for cancer therapy
Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2342 · Cited by 1,666
Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice
Sonveaux, P., Végran, F., Schroeder, T., Wergin, M. C., Verrax, J., Rabbani, Z. N., De Saedeleer, C. J., Kennedy, K. M., Diepart, C., Jordan, B. F., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36843 · Cited by 1,624
Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing
Guzy, R. D., Hoyos, B., Robin, E., Chen, H., Liu, L., Mansfield, K. D., Simon, M. C., Hammerling, U., & Schumacker, P. T. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.05.001 · Cited by 1,545
Brugarolas, J., Lei, K., Hurley, R. L., Manning, B. D., Reiling, J. H., Hafen, E., Witters, L. A., Ellisen, L. W., & Kaelin, W. G. (2004) · Genes & Development · doi:10.1101/gad.1256804 · Cited by 1,384 · cited 1×
“The mechanisms include activation of the tuberous sclerosis 1 (TSC1)–TSC2 complex through the HIF1 target gene DNA-damage-inducible transcript 4 ( DDIT4 ; also known as REDD1”
BackgroundHypoxia promotes invasive growth by transcriptional activation of the met protooncogene
Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., & Comoglio, P. M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00085-0 · Cited by 1,311
The Control of the Metabolic Switch in Cancers by Oncogenes and Tumor Suppressor Genes
Levine, A. J., & Puzio-Kuter, A. M. (2010) · Science · doi:10.1126/science.1193494 · Cited by 1,243
Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer
Macheda, M. L., Rogers, S., & Best, J. D. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20166 · Cited by 1,229
Hypoxia, DNA repair and genetic instability
Bristow, R. G., & Hill, R. P. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2344 · Cited by 1,140
Nordlund, P., & Reichard, P. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142443 · Cited by 1,079
Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response
Dewhirst, M. W., Cao, Y., & Moeller, B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2397 · Cited by 1,022
Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors
Moeller, B. J., Cao, Y., Li, C. Y., & Dewhirst, M. W. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00115-1 · Cited by 996
Nordsmark, M., Bentzen, S. M., Rudat, V., Brizel, D., Lartigau, E., Stadler, P., Becker, A., Adam, M., Molls, M., Dunst, J., et al. (2005) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2005.06.038 · Cited by 953
Hypoxia signalling through mTOR and the unfolded protein response in cancer
Wouters, B. G., & Koritzinsky, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2501 · Cited by 894
Ullah, M. S., Davies, A. J., & Halestrap, A. P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m511397200 · Cited by 890
Rouschop, K. M. A., van den Beucken, T., Dubois, L., Niessen, H., Bussink, J., Savelkouls, K., Keulers, T., Mujcic, H., Landuyt, W., Voncken, J. W., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40027 · Cited by 829
Maintaining genome stability at the replication fork
Branzei, D., & Foiani, M. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2852 · Cited by 786
Kioi, M., Vogel, H., Schultz, G., Hoffman, R. M., Harsh, G. R., & Brown, J. M. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40283 · Cited by 773
Lou, Y., McDonald, P. C., Oloumi, A., Chia, S., Ostlund, C., Ahmadi, A., Kyle, A., auf dem Keller, U., Leung, S., Huntsman, D., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4261 · Cited by 755
Chiche, J., Ilc, K., Laferrière, J., Trottier, E., Dayan, F., Mazure, N. M., Brahimi-Horn, M. C., & Pouysségur, J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2470 · Cited by 750
ER stress‐regulated translation increases tolerance to extreme hypoxia and promotes tumor growth
Bi, M., Naczki, C., Koritzinsky, M., Fels, D., Blais, J., Hu, N., Harding, H., Novoa, I., Varia, M., Raleigh, J., et al. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600777 · Cited by 729
Detection and Characterization of Tumor Hypoxia Using pO 2 Histography
Vaupel, P., Höckel, M., & Mayer, A. (2007) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1628 · Cited by 728
Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer
Chiche, J., Brahimi‐Horn, M. C., & Pouysségur, J. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00994.x · Cited by 667
Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative pathway
Isaacs, J. S., Jung, Y.-J., Mimnaugh, E. G., Martinez, A., Cuttitta, F., & Neckers, L. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204733200 · Cited by 663
Hypoxia, Clonal Selection, and the Role of HIF-1 in Tumor Progression
Semenza, G. L. (2000) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409230091169186 · Cited by 654
A general mechanism for microsomal activation of quinone anticancer agents to free radicals.
Bachur, N. R., Gordon, S. L., & Gee, M. V. (1978) · PubMed · Cited by 639
HIF-1 as a target for drug development
Giaccia, A., Siim, B. G., & Johnson, R. S. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1199 · Cited by 631 · cited 1×
“Multiple components of the HIF1 signalling pathway have been identified as candidate drug target”
BackgroundNitric oxide synthase activity in human breast cancer
Thomsen, L., Miles, D., Happerfield, L., Bobrow, L., Knowles, R., & Moncada, S. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.274 · Cited by 626
Melillo, G., Musso, T., Sica, A., Taylor, L. S., Cox, G. W., & Varesio, L. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.6.1683 · Cited by 626
Tatum, J. L. (2006) · International Journal of Radiation Biology · doi:10.1080/09553000601002324 · Cited by 620
Hypoxia-induced energy stress regulates mRNA translation and cell growth
Liu, L., Cash, T. P., Jones, R. G., Keith, B., Thompson, C. B., & Simon, M. C. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.010 · Cited by 607
Mitomycins and Porfiromycin: Chemical Mechanism of Activation and Cross-linking of DNA
Iyer, V. N., & Szybalski, W. (1964) · Science · doi:10.1126/science.145.3627.55 · Cited by 570
XBP1 Is Essential for Survival under Hypoxic Conditions and Is Required for Tumor Growth
Romero-Ramirez, L., Cao, H., Nelson, D., Hammond, E., Lee, A.-H., Yoshida, H., Mori, K., Glimcher, L. H., Denko, N. C., Giaccia, A. J., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1606 · Cited by 570
Coordination of ER and oxidative stress signaling: The PERK/Nrf2 signaling pathway
Cullinan, S. B., & Diehl, J. A. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.09.018 · Cited by 554
Rischin, D., Hicks, R. J., Fisher, R., Binns, D., Corry, J., Porceddu, S., & Peters, L. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.2878 · Cited by 541
Papandreou, I., Denko, N. C., Olson, M., Van Melckebeke, H., Lust, S., Tam, A., Solow-Cordero, D. E., Bouley, D. M., Offner, F., Niwa, M., et al. (2011) · Blood · doi:10.1182/blood-2010-08-303099 · Cited by 489
Konstantinopoulos, P. A., Spentzos, D., Karlan, B. Y., Taniguchi, T., Fountzilas, E., Francoeur, N., Levine, D. A., & Cannistra, S. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.5719 · Cited by 483
Synthetic lethal screen identification of chemosensitizer loci in cancer cells
Whitehurst, A. W., Bodemann, B. O., Cardenas, J., Ferguson, D., Girard, L., Peyton, M., Minna, J. D., Michnoff, C., Hao, W., Roth, M. G., et al. (2007) · Nature · doi:10.1038/nature05697 · Cited by 474
Chemical Radiosensitizers for Use in Radiotherapy
Wardman, P. (2007) · Clinical Oncology · doi:10.1016/j.clon.2007.03.010 · Cited by 447
Tu, B. P., & Weissman, J. S. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00696-2 · Cited by 433
Marin-Hernandez, A., Gallardo-Perez, J., Ralph, S., Rodriguez-Enriquez, S., & Moreno-Sanchez, R. (2009) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955709788922610 · Cited by 433
Macrophage Responses to Hypoxia
Lewis, C., & Murdoch, C. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62038-x · Cited by 413
Chang, C.-J., Yang, J.-Y., Xia, W., Chen, C.-T., Xie, X., Chao, C.-H., Woodward, W. A., Hsu, J.-M., Hortobagyi, G. N., & Hung, M.-C. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.035 · Cited by 408
Erler, J. T., Cawthorne, C. J., Williams, K. J., Koritzinsky, M., Wouters, B. G., Wilson, C., Miller, C., Demonacos, C., Stratford, I. J., & Dive, C. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.7.2875-2889.2004 · Cited by 400
Regulation of autophagy by ATF4 in response to severe hypoxia
Rzymski, T., Milani, M., Pike, L., Buffa, F., Mellor, H. R., Winchester, L., Pires, I., Hammond, E., Ragoussis, I., & Harris, A. L. (2010) · Oncogene · doi:10.1038/onc.2010.191 · Cited by 384
Rischin, D., Peters, L. J., O'Sullivan, B., Giralt, J., Fisher, R., Yuen, K., Trotti, A., Bernier, J., Bourhis, J., Ringash, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4449 · Cited by 380
Lee, K. P. K., Dey, M., Neculai, D., Cao, C., Dever, T. E., & Sicheri, F. (2008) · Cell · doi:10.1016/j.cell.2007.10.057 · Cited by 379
SR 4233 (Tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours
Brown, J. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.220 · Cited by 366
Evaluation of HIF-1 inhibitors as anticancer agents
Semenza, G. L. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.08.006 · Cited by 363
Down-Regulation of Rad51 and Decreased Homologous Recombination in Hypoxic Cancer Cells
Bindra, R. S., Schaffer, P. J., Meng, A., Woo, J., Måseide, K., Roth, M. E., Lizardi, P., Hedley, D. W., Bristow, R. G., & Glazer, P. M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8504-8518.2004 · Cited by 356
Wouters, B. G., & Brown, J. M. (1997) · Radiation Research · doi:10.2307/3579620 · Cited by 341
Chan, N., Koritzinsky, M., Zhao, H., Bindra, R., Glazer, P. M., Powell, S., Belmaaza, A., Wouters, B., & Bristow, R. G. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5472 · Cited by 328
Graeser, M., McCarthy, A., Lord, C. J., Savage, K., Hills, M., Salter, J., Orr, N., Parton, M., Smith, I. E., Reis-Filho, J. S., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1027 · Cited by 327
The role of catalytic superoxide formation in the O2 inhibition of nitroreductase
Mason, R. P., & Holtzman, J. L. (1975) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(75)90163-1 · Cited by 308
Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues
Siegel, D., & Ross, D. (2000) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(00)00310-5 · Cited by 298
MacLeod, A. K., McMahon, M., Plummer, S. M., Higgins, L. G., Penning, T. M., Igarashi, K., & Hayes, J. D. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp176 · Cited by 297
Gallagher, S. M., Castorino, J. J., Wang, D., & Philp, N. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3184 · Cited by 288
Hammond, E. M., Dorie, M. J., & Giaccia, A. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212360200 · Cited by 284
Chang, Q., Jurisica, I., Do, T., & Hedley, D. W. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4049 · Cited by 272
Li, Y., Wang, Y., Kim, E., Beemiller, P., Wang, C.-Y., Swanson, J., You, M., & Guan, K.-L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m705231200 · Cited by 269
Ovens, M. J., Davies, A. J., Wilson, M. C., Murray, C. M., & Halestrap, A. P. (2010) · Biochemical Journal · doi:10.1042/bj20091515 · Cited by 260
IV HOSPITALS IN THE UNITED STATES
Maitland, C. T. (1948) · The Lancet · doi:10.1016/s0140-6736(48)90145-7 · Cited by 254
Monocarboxylate transporter MCT1 is a target for immunosuppression
Murray, C. M., Hutchinson, R., Bantick, J. R., Belfield, G. P., Benjamin, A. D., Brazma, D., Bundick, R. V., Cook, I. D., Craggs, R. I., Edwards, S., et al. (2005) · Nature Chemical Biology · doi:10.1038/nchembio744 · Cited by 248
Kaluz, S., Kaluzová, M., Liao, S.-Y., Lerman, M., & Stanbridge, E. J. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.01.001 · Cited by 248
Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment
Chan, N., Pires, I. M., Bencokova, Z., Coackley, C., Luoto, K. R., Bhogal, N., Lakshman, M., Gottipati, P., Oliver, F. J., Helleday, T., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2352 · Cited by 244
Cancer Stem Cells, Hypoxia and Metastasis
Hill, R. P., Marie-Egyptienne, D. T., & Hedley, D. W. (2009) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2008.12.002 · Cited by 238
Design of anticancer prodrugs for reductive activation
Chen, Y., & Hu, L. (2009) · Medicinal Research Reviews · doi:10.1002/med.20137 · Cited by 238
Targeting hypoxia cell signaling for cancer therapy
Melillo, G. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9059-x · Cited by 230
“Translating” Tumor Hypoxia: Unfolded Protein Response (UPR)–Dependent and UPR-Independent Pathways
Koumenis, C., & Wouters, B. G. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0150 · Cited by 228
Preferential activation of mitomycin C to cytotoxic metabolites by hypoxic tumor cells.
Kennedy, K. A., Rockwell, S., & Sartorelli, A. C. (1980) · PubMed · Cited by 219
Oxygen-dependent ATF-4 stability is mediated by the PHD3 oxygen sensor
Köditz, J., Nesper, J., Wottawa, M., Stiehl, D. P., Camenisch, G., Franke, C., Myllyharju, J., Wenger, R. H., & Katschinski, D. M. (2007) · Blood · doi:10.1182/blood-2007-06-094441 · Cited by 214
Potent and Selective Inhibitors of the Inositol-requiring Enzyme 1 Endoribonuclease
Volkmann, K., Lucas, J. L., Vuga, D., Wang, X., Brumm, D., Stiles, C., Kriebel, D., Der-Sarkissian, A., Krishnan, K., Schweitzer, C., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.199737 · Cited by 214
Targeting the hypoxia-inducible factor (HIF) pathway in cancer
Poon, E., Harris, A. L., & Ashcroft, M. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409001173 · Cited by 213
Yu, K., Shi, C., Toral-Barza, L., Lucas, J., Shor, B., Kim, J. E., Zhang, W.-G., Mahoney, R., Gaydos, C., Tardio, L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2340 · Cited by 206
Molecular imaging of hypoxia with radiolabelled agents
Mees, G., Dierckx, R., Vangestel, C., & Van de Wiele, C. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1195-9 · Cited by 201
Effects of Acute versus Chronic Hypoxia on DNA Damage Responses and Genomic Instability
Pires, I. M., Bencokova, Z., Milani, M., Folkes, L. K., Li, J.-L., Stratford, M. R., Harris, A. L., & Hammond, E. M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2715 · Cited by 200
Potential bioreductive alkylating agents. 1. Benzoquinone derivatives
Lin, A. J., Cosby, L. A., Shansky, C. W., & Sartorelli, A. C. (1972) · Journal of Medicinal Chemistry · doi:10.1021/jm00282a011 · Cited by 198
A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death
Wood, T. E., Dalili, S., Simpson, C. D., Hurren, R., Mao, X., Saiz, F. S., Gronda, M., Eberhard, Y., Minden, M. D., Bilan, P. J., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0569 · Cited by 195
Ware, D. C., Palmer, B. D., Wilson, W. R., & Denny, W. A. (1993) · Journal of Medicinal Chemistry · doi:10.1021/jm00065a006 · Cited by 193
Self-citationStructural Adaptation and Heterogeneity of Normal and Tumor Microvascular Networks
Pries, A. R., Cornelissen, A. J. M., Sloot, A. A., Hinkeldey, M., Dreher, M. R., Höpfner, M., Dewhirst, M. W., & Secomb, T. W. (2009) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000394 · Cited by 192
Martinive, P., Defresne, F., Bouzin, C., Saliez, J., Lair, F., Grégoire, V., Michiels, C., Dessy, C., & Feron, O. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2056 · Cited by 190
Guise, C. P., Abbattista, M. R., Singleton, R. S., Holford, S. D., Connolly, J., Dachs, G. U., Fox, S. B., Pollock, R., Harvey, J., Guilford, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3237 · Cited by 185
Self-citationMohindra, J. K., & Rauth, A. M. (1976) · PubMed · Cited by 182
18F-EF5: A New PET Tracer for Imaging Hypoxia in Head and Neck Cancer
Komar, G., Seppänen, M., Eskola, O., Lindholm, P., Grönroos, T. J., Forsback, S., Sipilä, H., Evans, S. M., Solin, O., & Minn, H. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.053785 · Cited by 181
AQ4N: a new approach to hypoxia-activated cancer chemotherapy
Patterson, L. H., & McKeown, S. R. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1564 · Cited by 178
Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis
Jubb, A. M., Buffa, F. M., & Harris, A. L. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00944.x · Cited by 175
Hicks, K. O., Pruijn, F. B., Secomb, T. W., Hay, M. P., Hsu, R., Brown, J. M., Denny, W. A., Dewhirst, M. W., & Wilson, W. R. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj306 · Cited by 168
Self-citationKurtoglu, M., Maher, J. C., & Lampidis, T. J. (2007) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1714 · Cited by 163
Weiss, G. J., Infante, J. R., Chiorean, E. G., Borad, M. J., Bendell, J. C., Molina, J. R., Tibes, R., Ramanathan, R. K., Lewandowski, K., Jones, S. F., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3425 · Cited by 160
Hypoxia-induced genetic instability—a calculated mechanism underlying tumor progression
Huang, E. L., Bindra, R. S., Glazer, P. M., & Harris, A. L. (2006) · Journal of Molecular Medicine · doi:10.1007/s00109-006-0133-6 · Cited by 158
Colucci, M. A., Couch, G. D., & Moody, C. J. (2007) · Organic & Biomolecular Chemistry · doi:10.1039/b715270a · Cited by 156
Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug
Hu, J., Handisides, D. R., Valckenborgh, E. V., Raeve, H. D., Menu, E., Broek, I. V., Liu, Q., Sun, J. D., Camp, B. V., Hart, C. P., et al. (2010) · Blood · doi:10.1182/blood-2010-02-269126 · Cited by 152
Wardman, P. (2001) · Current Medicinal Chemistry · doi:10.2174/0929867013372959 · Cited by 150
Patterson, L. H. (1993) · Cancer and Metastasis Reviews · doi:10.1007/bf00689805 · Cited by 146
Knox, R. J., Boland, M. P., Friedlos, F., Coles, B., Southan, C., & Roberts, J. J. (1988) · Biochemical Pharmacology · doi:10.1016/0006-2952(88)90336-x · Cited by 146
Connors, T. A., & Whisson, M. E. (1966) · Nature · doi:10.1038/210866b0 · Cited by 142
Fels, D. R., Ye, J., Segan, A. T., Kridel, S. J., Spiotto, M. T., Olson, M., Koong, A. C., & Koumenis, C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2873 · Cited by 140
The experimental development of bioreductive drugs and their role in cancer therapy
Workman, P., & Stratford, I. J. (1993) · Cancer and Metastasis Reviews · doi:10.1007/bf00689802 · Cited by 135
Mitomycin C: Chemical and Biological Studies on Alkylation
Schwartz, H. S., Sodergren, J. E., & Philips, F. S. (1963) · Science · doi:10.1126/science.142.3596.1181 · Cited by 134
Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin.
Koch, C. J. (1993) · PubMed · Cited by 132
Hicks, K. O., Siim, B. G., Jaiswal, J. K., Pruijn, F. B., Fraser, A. M., Patel, R., Hogg, A., Liyanage, H. D. S., Dorie, M. J., Brown, J. M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1439 · Cited by 132
Self-citationMetabolism of SR 4233 by Chinese hamster ovary cells: basis of selective hypoxic cytotoxicity.
Baker, M., Zeman, E. M., Hirst, V. K., & Brown, J. M. (1988) · PubMed · Cited by 121
Targeting Hypoxic Cells through the DNA Damage Response
Olcina, M. M., Lecane, P. S., & Hammond, E. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0286 · Cited by 119
Hedley, D. W., Pintilie, M., Woo, J. M. P., Morrison, A. J., Birle, D. C., Fyles, A., Milosevic, M., & Hill, R. P. (2003) · PubMed · Cited by 117
Willers, H., Taghian, A. G., Luo, C., Treszezamsky, A. D., Sgroi, D. C., & Powell, S. N. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0149 · Cited by 117
Reductive activation of mitomycin C by NADH:cytochrome b5 reductase.
Hodnick, W. F., & Sartorelli, A. C. (1993) · PubMed · Cited by 116
Efficient Hypoxic Activation of the Anticancer Agent AQ4N by CYP2S1 and CYP2W1
Nishida, C. R., Lee, M., & de Montellano, P. R. O. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.065045 · Cited by 115
Inhibition of ATR Leads to Increased Sensitivity to Hypoxia/Reoxygenation
Hammond, E. M., Dorie, M. J., & Giaccia, A. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1520 · Cited by 115
Regulation of Autophagy Through Multiple Independent Hypoxic Signaling Pathways
Rouschop, K. M. A., & Wouters, B. G. (2009) · Current Molecular Medicine · doi:10.2174/156652409788167131 · Cited by 114
Ahlskog, J., Schliemann, C., Mårlind, J., Qureshi, U., Ammar, A., Pedley, R. B., & Neri, D. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605200 · Cited by 110
Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents.
Garner, A. P., Paine, M. J. I., Rodríguez‐Crespo, I., Chinje, E. C., de Montellano, P. R. O., Stratford, I. J., Tew, D. G., & Wolf, C. R. (1999) · PubMed · Cited by 110
Spiotto, M. T., Banh, A., Papandreou, I., Cao, H., Galvez, M. G., Gurtner, G. C., Denko, N. C., Le, Q., & Koong, A. C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2747 · Cited by 106
PET of Hypoxia with89Zr-Labeled cG250-F(ab′)2in Head and Neck Tumors
Hoeben, B. A. W., Kaanders, J. H. A. M., Franssen, G. M., Troost, E. G. C., Rijken, P. F. J. W., Oosterwijk, E., van Dongen, G. A. M. S., Oyen, W. J. G., Boerman, O. C., & Bussink, J. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.073189 · Cited by 105
Hicks, K. O., Fleming, Y., Siim, B. G., Koch, C. J., & Wilson, W. R. (1998) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(98)00268-5 · Cited by 100
Self-citationPencreach, E., Guérin, É., Nicolet, C., Lelong-Rebel, I. H., Voegeli, A., Oudet, P., Larsen, A. K., Gaub, M., & Guénot, D. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0889 · Cited by 97
INDUCIBLE NITRIC OXIDE SYNTHASE WITH TRANSITIONAL CELL CARCINOMA OF THE BLADDER
Swana, H. S., Smith, S. D., Perrotta, P. L., SAITO, N., Wheeler, M. A., & WEISS, R. M. (1999) · The Journal of Urology · doi:10.1016/s0022-5347(01)61985-2 · Cited by 95
Comparison of hypoxia-induced replication arrest with hydroxyurea and aphidicolin-induced arrest
Hammond, E. M., Green, S., & Giaccia, A. J. (2003) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2003.08.017 · Cited by 91
The HIF-1-active microenvironment: An environmental target for cancer therapy
Kizaka‐Kondoh, S., Tanaka, S., Harada, H., & Hiraoka, M. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.01.006 · Cited by 89
Yang, J., Ahmed, A., Poon, E., Perusinghe, N. P., Brandon, A. D. H., Box, G., Valenti, M. R., Eccles, S. A., Rouschop, K. M. A., Wouters, B. G., et al. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00959-08 · Cited by 86
Cowen, R. L., Williams, K. J., Chinje, E. C., Jaffar, M., Sheppard, F. C. D., Telfer, B. A., Wind, N. S., & Stratford, I. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2698 · Cited by 86
Ahn, G., Botting, K. J., Patterson, A. V., Ware, D. C., Tercel, M., & Wilson, W. R. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.03.007 · Cited by 81
Self-citationTuttle, S. W., Maity, A. M., Oprysko, P. R., Kachur, A. V., Ayene, I. S., Biaglow, J. E., & Koch, C. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700327200 · Cited by 80
Birtwistle, J., Hayden, R. E., Khanim, F. L., Green, R. M., Pearce, C., Davies, N., Wake, N. C., Schrewe, H., Ride, J. P., Chipman, J. K., et al. (2009) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2008.12.010 · Cited by 79
Lampidis, T. J., Kurtoğlu, M., Maher, J. C., Liu, H., Krishan, A., Sheft, V., Szymański, S., Fokt, I., Rudnicki, W. R., Ginalski, K., et al. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0207-8 · Cited by 79
Potential Bioreductive Alkylating Agents
Ai, L., Cosby, L. A., & Sartorelli, A. C. (1976) · ACS symposium series · doi:10.1021/bk-1976-0030.ch004 · Cited by 78
Tendler, D. S., Bao, C., Wang, T., Huang, E. L., Ratovitski, E. A., Pardoll, D., & Lowenstein, C. J. (2001) · PubMed · Cited by 77
Raleigh, S. M., Wanogho, E., Burke, M. D., McKeown, S. R., & Patterson, L. H. (1998) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(98)00308-3 · Cited by 76
Kyle, A. H., & Minchinton, A. I. (1999) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050886 · Cited by 75
Hypoxia-induced Expression of Carbonic Anhydrase 9 Is Dependent on the Unfolded Protein Response
van den Beucken, T., Koritzinsky, M., Niessen, H. E. C., Dubois, L. J., Savelkouls, K. G. M., Mujčić, H., Jutten, B., Kopáček, J., Pastoreková, S., van der Kogel, A. J., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.006510 · Cited by 75
Wilson, W. R., Hicks, K. O., Pullen, S. M., Ferry, D. M., Helsby, N. A., & Patterson, A. V. (2007) · Radiation Research · doi:10.1667/rr0807.1 · Cited by 75
Self-citationHicks, K. O., Myint, H., Patterson, A. V., Pruijn, F. B., Siim, B. G., Patel, K., & Wilson, W. R. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.05.049 · Cited by 74
Self-citationRivera, S. P., Wang, F., Saarikoski, S. T., Taylor, R. T., Chapman, B., Zhang, R., & Hankinson, O. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m609617200 · Cited by 73
Multimodality imaging of hypoxia in preclinical settings.
Mason, R. P., Zhao, D., Pacheco‐Torres, J., Cui, W., Kodibagkar, V. D., Gulaka, P., Hao, G., Thorpe, P. E., Hahn, E. W., & Peschke, P. (2010) · PubMed · Cited by 70
Hypoxic Tumors and Their Effect on Immune Cells and Cancer Therapy
Yotnda, P., Wu, D., & Swanson, A. M. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-786-0_1 · Cited by 70
NRH:quinone oxidoreductase 2 (NQO2) catalyzes metabolic activation of quinones and anti-tumor drugs
Celli, C. M., Tran, N., Knox, R. J., & Jaiswal, A. K. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.04.029 · Cited by 69
Evans, J., Chernikova, S. B., Kachnic, L. A., Banáth, J. P., Sordet, O., Delahoussaye, Y. M., Treszezamsky, A. D., Chon, B. H., Feng, Z., Gu, Y., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-06-4497 · Cited by 69
Self-citationGu, Y., Patterson, A. V., Atwell, G. J., Chernikova, S. B., Brown, J. M., Thompson, L. H., & Wilson, W. R. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1209 · Cited by 69
Self-citationHYPOXIC CELL SENSITISERS IN RADIOTHERAPY
ADAMS, G. E., Fowler, J. F., Dische, S., & Thomlinson, R. H. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91285-x · Cited by 66
Shinde, S. S., Hay, M. P., Patterson, A. V., Denny, W. A., & Anderson, R. F. (2009) · Journal of the American Chemical Society · doi:10.1021/ja906860a · Cited by 64
Self-citationTercel, M., Lee, A. E., Hogg, A., Anderson, R. F., Lee, H. H., Siim, B. G., Denny, W. A., & Wilson, W. R. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010202l · Cited by 63
Self-citationMarotta, D. E., Karar, J., Jenkins, W. T., Kumanova, M., Jenkins, K. W., Tobias, J. W., Baldwin, D. A., Hatzigeorgiou, A. G., Alexiou, P., Evans, S. M., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3061 · Cited by 62
Targeting tumors with hypoxia-activated cytotoxins
Ahn, G., & Brown, M. (2007) · Frontiers in bioscience · doi:10.2741/2329 · Cited by 61
The Unfolded Protein Response and Integrated Stress Response to Anoxia
Rzymski, T., & Harris, A. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2126 · Cited by 60
A Novel Design Strategy for Stable Metal Complexes of Nitrogen Mustards as Bioreductive Prodrugs
Parker, L. L., Lacy, S. M., Farrugia, L. J., Evans, C., Robins, D. J., O’Hare, C. C., Hartley, J. A., Jaffar, M., & Stratford, I. J. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049866w · Cited by 60
Chowdhury, G., Junnotula, V., Daniels, J. S., Greenberg, M. M., & Gates, K. S. (2007) · Journal of the American Chemical Society · doi:10.1021/ja074432m · Cited by 58
Parveen, I., Naughton, D. P., WHISH, W. J. D., & Threadgill, M. D. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00306-6 · Cited by 57
Evaluation of bioreductive drugs in multicell spheroids
Durand, R. E., & Olive, P. L. (1992) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(92)90504-b · Cited by 55
Wang, W., & Jaiswal, A. K. (2005) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2005.10.063 · Cited by 53
Oxygen‐mediated endocytosis in cancer
Wang, Y., & Ohh, M. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01016.x · Cited by 50
Wilson, W. R., Moselen, J. W., Cliffe, S., Denny, W. A., & Ware, D. C. (1994) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(94)90283-6 · Cited by 49
Self-citationHoogsteen, I. J., Lok, J., Marres, H. A. M., Takes, R. P., Rijken, P. F. J. W., van der Kogel, A. J., & Kaanders, J. H. A. M. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.07.012 · Cited by 48
Hay, M. P., Pchalek, K., Pruijn, F. B., Hicks, K. O., Siim, B. G., Anderson, R. F., Shinde, S. S., Phillips, V., Denny, W. A., & Wilson, W. R. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm701037w · Cited by 46
Self-citationThomson, P., Naylor, M. A., Everett, S. A., Stratford, M. R. L., Lewis, G., Hill, S. A., Patel, K. B., Wardman, P., & Davis, P. D. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0429 · Cited by 46
Tercel, M., Atwell, G. J., Yang, S., Ashoorzadeh, A., Stevenson, R. J., Botting, K. J., Gu, Y., Mehta, S. Y., Denny, W. A., Wilson, W. R., et al. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201004456 · Cited by 46
Self-citationHicks, K. O., Siim, B. G., Pruijn, F. B., & Wilson, W. R. (2004) · Radiation Research · doi:10.1667/rr3178 · Cited by 46
Self-citationPreferential Cytotoxicity of 5-Thio-d-glucose Against Hypoxic Tumor Cells2
Song, C. W., Clement, J. J., & Levitt, S. H. (1976) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/57.3.603 · Cited by 45
Haffty, B. G., Son, Y. H., Wilson, L. D., Papac, R. J., FISCHER, D. B., Rockwell, S., Sartorelli, A. C., Ross, D. A., Sasaki, C. T., & Fischer, J. J. (1997) · Radiation Oncology Investigations · doi:10.1002/(sici)1520-6823(1997)5:5<213::aid-roi1>3.0.co;2-0 · Cited by 44
Bis-bioreductive agents as hypoxia-selective cytotoxins: Nitracrine N-oxide
Wilson, W. R., van Zijl, P., & Denny, W. A. (1992) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(92)90505-c · Cited by 44
Self-citationPruijn, F. B., Patel, K., Hay, M. P., Wilson, W. R., & Hicks, K. O. (2008) · Australian Journal of Chemistry · doi:10.1071/ch08240 · Cited by 43
Self-citationYan, C., Kepa, J. K., Siegel, D. M., Stratford, I. J., & Ross, D. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.050401 · Cited by 42
Jain, A. K., Phillips, R. M., Scally, A., Lenaz, G., Beer, M., & Puri, R. (2009) · Urology · doi:10.1016/j.urology.2007.12.062 · Cited by 40
Marshall, R. S., & Rauth, A. M. (1988) · PubMed · Cited by 40
Reductive Heme-Dependent Activation of theN-Oxide Prodrug AQ4N by Nitric Oxide Synthase
Nishida, C. R., & de Montellano, P. R. O. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800496s · Cited by 39
Everett, S. A., Naylor, M. A., Patel, K. B., Stratford, M. R. L., & Wardman, P. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00171-7 · Cited by 37
Tumor Hypoxia as a Modifier of DNA Strand Break and Cross-Link Repair
Chan, N. H. L., Koch, C. J., & Bristow, R. G. (2009) · Current Molecular Medicine · doi:10.2174/156652409788167050 · Cited by 37
Siim, B. G., Atwell, G. J., & Wilson, W. R. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.357 · Cited by 37
Self-citationTercel, M., Wilson, W. R., Anderson, R. F., & Denny, W. A. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm9507791 · Cited by 35
Self-citationPhase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1
Danson, S. J., Johnson, P., Ward, T. H., Dawson, M. J., Denneny, O., Dickinson, G. L., Aarons, L. J., Watson, A. J., Jowle, D., Cummings, J., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq638 · Cited by 34
Combining bioreductive drugs and radiation for the treatment of solid tumors
Stratford, I. J., Williams, K. J., Cowen, R. L., & Jaffar, M. (2003) · Seminars in Radiation Oncology · doi:10.1053/srao.2003.50008 · Cited by 29
CHK2-Dependent Phosphorylation of BRCA1 in Hypoxia
Gibson, S. L., Bindra, R. S., & Glazer, P. M. (2006) · Radiation Research · doi:10.1667/rr0660.1 · Cited by 28
Bioreductively Activated Lysyl Oxidase Inhibitors against Hypoxic Tumours
Granchi, C., Funaioli, T., Erler, J. T., Giaccia, A. J., Macchia, M., & Minutolo, F. (2009) · ChemMedChem · doi:10.1002/cmdc.200900247 · Cited by 27
Chinje, E. C., Cowen, R. L., Feng, J., Sharma, S. P., Wind, N. S., Harris, A. L., & Stratford, I. J. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.6.1248 · Cited by 27
Measurement of Electrode Potentials in Living and Dead Tissues
Cater, D. B., & Phillips, A. F. (1954) · Nature · doi:10.1038/174121b0 · Cited by 25
Chandor-Proust, A., Dijols, S., Ramassamy, B., Frapart, Y., Mansuy, D., Stuehr, D. J., Helsby, N. A., & Boucher, J. (2008) · Chemical Research in Toxicology · doi:10.1021/tx7004234 · Cited by 24
Aerobic reduction of 5-nitro-2-furaldehyde semicarbazone by rat liver xanthine dehydrogenase
Kutcher, W. W., & McCalla, D. R. (1984) · Biochemical Pharmacology · doi:10.1016/0006-2952(84)90465-9 · Cited by 23
Cintio, A. D., Gennaro, E. D., & Budillon, A. (2009) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489210789702172 · Cited by 20
Kan, K. (2010) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2010.583 · Cited by 19
Adikesavan, A. K., Barrios, R. J., & Jaiswal, A. K. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4480 · Cited by 16
Chinje, E. C., Williams, K. J., Telfer, B. A., Wood, P. J., van der Kogel, A. J., & Stratford, I. J. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600032 · Cited by 11
Nitroaromatic betulin derivatives as redox cycling agents
Miškiniene, V., Dičkancaitė, E., Nemeikaitė-Čėnienė, A., & Čėnas, N. (1997) · IUBMB Life · doi:10.1080/15216549700202791 · Cited by 9
Patterson, A. V., Jaswail, J., Syddall, S. P., Abbattista, M. R., van Leeuwen, W. F., Puryer, M. A., Thompson, A., Hsu, A., Mehta, S. Y., Pruijn, A., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-09-b76 · Cited by 7
Self-citationTherapeutic Targeting of the Hypoxic Microenvironment in Acute Lymphocytic Leukemia.
Konopleva, M. Y., Benito, J., Shi, Y., Konoplev, S. N., Kornblau, S. M., Frolova, O., Zweidler‐McKay, P. A., Qiu, Y., Wilson, W. R., Campana, D., et al. (2009) · Blood · doi:10.1182/blood.v114.22.2040.2040 · Cited by 4
Self-citationAbstract 67: Selective cytotoxic targeting of von Hippel-Lindau-deficient renal cell carcinoma cells
Lai, E. W., Chan, D. A., Hay, M. P., & Giaccia, A. J. (2010) · Cancer Research · doi:10.1158/1538-7445.am10-67 · Cited by 3
Self-citationEF5 as a predictive biomarker for activation of the new hypoxia-targeting prodrug SN30000.
Wang, J., Foehrenbacher, A., Su, J., Patel, R., Hay, M. P., Hicks, K. O., & Wilson, W. R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.e13597 · Cited by 3
Self-citationGuise, C. P., Tipparaju, S. R., Abbattista, M. R., Dachs, G. U., Su, J., Foehrenbacher, A., Wilson, W. R., & Patterson, A. V. (2010) · Cancer Research · doi:10.1158/1538-7445.am10-453 · Cited by 1
Self-citation
Cited by
Yunna, C., Mengru, H., Lei, W., & Weidong, C. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173090 · Cited by 2,454
Reactive Oxygen Species (ROS)-Based Nanomedicine
Yang, B., Chen, Y., & Shi, J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00626 · Cited by 2,443
The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy
Muz, B., de la Puente, P., Azab, F., & Azab, A. K. (2015) · Hypoxia · doi:10.2147/hp.s93413 · Cited by 2,066
“Radiation and drug resistance Resistance of cancer cells to treatment-induced apoptosis is one of the biggest obstacles in cancer therapy.(92) A vast number of cancer patients relapse and suffer from recurring tumors as a result of micro-residual disease, the resistant subpopulation of cancer cells, leading to local r…”
BackgroundReactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
Zhou, Z., Song, J., Nie, L., & Chen, X. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00271d · Cited by 2,098
Role of hypoxia in cancer therapy by regulating the tumor microenvironment
Jing, X., Yang, F., Shao, C., Wei, K., Xie, M., Shen, H., & Shu, Y. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1089-9 · Cited by 2,054
Metadata
- Authors
- Wilson, W. R., & Hay, M. P.
- Affiliations
- University of Auckland (NZ)
- Corresponding author
- Wilson, William R.
- Venue
- Nature Reviews Cancer
- Published
- 2011-05-24
- Volume
- 11
- Issue
- 6
- Pages
- 393-410
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2024903578
- Cited by
- 3,172
- References
- 190
- Citations by year
- 2026: 109 · 2025: 165 · 2024: 196 · 2023: 206 · 2022: 268 · 2021: 298 · 2020: 319 · 2019: 238 · 2018: 274 · 2017: 238 · 2016: 223 · 2015: 188 · 2014: 164 · 2013: 156 · 2012: 102
- FWCI
- 10.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- ResearchSpace (University of Auckland) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- tumor hypoxia, cancer therapy, bioreductive prodrugs, chemoresistance, radioresistance (biology), angiogenesis, metastasis, cancer metabolism, genomic instability, patient stratification
- MeSH terms
- Antineoplastic Agents, Humans, Neoplasms, Prodrugs, Prognosis, Biomarkers, Tumor, Cell Hypoxia, Reactive Oxygen Species, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.